ArticleDrug design, development and therapy2026
Effect of Remimazolam versus Propofol Sedation on Postoperative Sleep Quality Following Gastroscopy: A Propensity Score-Matched Cohort Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Letter to the Editor Regarding "Effect of Remimazolam Versus Propofol Sedation on Postoperative Sleep Quality Following Gastroscopy: A Propensity Score-Matched Cohort Study" [Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Postoperative sleep disturbance is a prevalent complication following painless gastroscopy. Remimazolam, an ultra-short-acting benzodiazepine with rapid metabolism, offers theoretical advantages in preserving the postoperative sleep architecture. This study compared the effects of remimazolam and propofol sedation on postoperative sleep quality in patients undergoing painless gastroscopy. Patients and Methods: We conducted a retrospective cohort study of 802 patients who underwent painless gastroscopy. The participants received either remimazolam or propofol for procedural sedation. Propensity score matching balanced the baseline characteristics between the cohorts. The primary outcome was postoperative sleep quality, which was assessed using the Richards-Campbell Sleep Questionnaire (RCSQ). The second outcomes included intraoperative hemodynamics, recovery parameters, and adverse events. Conditional linear regression was used to evaluate the association between anesthetic choice and sleep outcomes. Sensitive analysis employing inverse probability of treatment weighting (IPTW) validated the robustness of the results. Results: The final analysis comprised 662 patients (331 patients per group). The post-matching baseline characteristics demonstrated excellent balance. The remimazolam cohort exhibited significantly superior postoperative RCSQ scores than the propofol cohort [median (IQR): 73.00 (64.00-80.00) vs 70.00 (59.00-80.00); P = 0.005], with notable improvements in sleep depth, nocturnal awakenings, and overall sleep quality. Remimazolam was associated with reduced intraoperative hypotension (5.4% vs 28.1%; P < 0.001) and injection pain (3.3% vs 18.7%; P < 0.001). Conversely, recovery time was prolonged and hiccup incidence increased with remimazolam (both P < 0.001). Multivariable analysis showed that remimazolam was independently associated with enhanced postoperative sleep (β = 7.985; 95% CI: 4.702-11.267; P < 0.001). The IPTW sensitivity analysis corroborated these findings. Conclusion: Remimazolam was associated with modestly improved postoperative sleep quality and hemodynamic stability compared with propofol, but also with longer recovery time and more hiccups than propofol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.